News

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.
A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.
The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...
Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.
Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...
NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...
Shares of PVH Corp. fell after hours on Wednesday after the Calvin Klein and Tommy Hilfiger parent cut its full-year profit outlook, citing the impact of tariffs on shipments heading into the U.S. The ...
Pride month is here, Bham! We’ve put together a guide of ways to directly join the fight against HIV + support all members of our LGBT+ community—from events to giveaways + more. 👇 NowPartner #bham # ...
The funding for 2 million people to receive the twice-yearly preventative treatment lenacapavir is ‘receding in the chaos’ of ...
The shift toward universal screening for diseases like hepatitis C, hepatitis B, and HIV removes part of the burden of ...